Amyotrophic Lateral Sclerosis: Review

Seminars in Neurology

Volumn 35, Issue 4, 2015, Pages 469-476

  Salameh, Johnny S ^a   Brown, Robert H ^a   Berry, James D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

amyotrophic lateral sclerosis; motor neuron disease; multidisciplinary care

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BODY WEIGHT; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; ENTERIC FEEDING; FALLING; GENE THERAPY; GENETICS; HUMAN; INTERPERSONAL COMMUNICATION; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY FAILURE; STEM CELL TRANSPLANTATION; STOMACH TUBE; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS;

EID: 84943395359     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0035-1558984     Document Type: Article

References (97)

1. Logroscino G., Traynor B. J., Hardiman O., et al. EURALS. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry: 2008; 79 1 6 11
2. Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V.; Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet: 1996; 347 9013 1425 1431
3. Silani V., Messina S., Poletti B., et al. The diagnosis of amyotrophic lateral sclerosis in 2010. Arch Ital Biol: 2011; 149 1 5 27
4. Chiò A., Logroscino G., Hardiman O., et al. Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler: 2009; 10 5-6 310 323
5. Rowland L. P., Mitsumoto H., Przybelski S. A. Amyotrophic lateral sclerosis, progressive muscular atrophy, and primary lateral sclerosis. In: Rowland L. P., Pedley T. A., eds. Merritt's Neurology. 12th ed. Philadelphia, PA Lippincott, Williams & Wilkins: 2010; 802 808
6. Brooks B. R., Miller R. G., Swash M., Munsat T. L.; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord: 2000; 1 5 293 299
7. Traynor B. J., Codd M. B., Corr B., Forde C., Frost E., Hardiman O. M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol: 2000; 57 8 1171 1176
8. de Carvalho M., Dengler R., Eisen A., et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol: 2008; 119 3 497 503
9. Paganoni S., Macklin E. A., Lee A., et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener: 2014; 15 5-6 453 456
10. Cellura E., Spataro R., Taiello A. C., La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg: 2012; 114 6 550 554
11. Williams J. R., Fitzhenry D., Grant L., Martyn D., Kerr D. A. Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol: 2013; 13 160
12. Atassi N., Nakano I., Mora J., et al. Development of a red flags symptom list to assist with early recognition and diagnosis of amyotrophic lateral sclerosis. Paper presented at: European Neurological Society June 9-12, 2012; Prague, Czech Republic
13. Phukan J., Elamin M., Bede P., et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry: 2012; 83 1 102 108
14. Arai T., Hasegawa M., Akiyama H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun: 2006; 351 3 602 611
15. Neumann M., Sampathu D. M., Kwong L. K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science: 2006; 314 5796 130 133
16. Murphy J., Henry R., Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol: 2007; 64 3 330 334
17. Murphy J. M., Henry R. G., Langmore S., Kramer J. H., Miller B. L., Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol: 2007; 64 4 530 534
18. Elamin M., Phukan J., Bede P., et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology: 2011; 76 14 1263 1269
19. Woolley S. C., York M. K., Moore D. H., et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler: 2010; 11 3 303 311
20. Abrahams S., Newton J., Niven E., Foley J., Bak T. H. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener: 2014; 15 1-2 9 14
21. Ravits J. M., La Spada A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology: 2009; 73 10 805 811
22. Grad L. I., Pokrishevsky E., Silverman J. M., Cashman N. R. Exosome-dependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding. Prion: 2014; 8 5 331 335
23. Grad L. I., Yerbury J. J., Turner B. J., et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A: 2014; 111 9 3620 3625
24. Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol: 2014; 262 (Pt B): 121 126
25. Rowland L. P., Shneider N. A. Amyotrophic lateral sclerosis. N Engl J Med: 2001; 344 22 1688 1700
26. Turner M. R., Parton M. J., Shaw C. E., Leigh P. N., Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry: 2003; 74 7 995 997
27. Kurtzke J. F. Epidemiology of amyotrophic lateral sclerosis. Adv Neurol: 1982; 36 281 302
28. Wijesekera L. C., Mathers S., Talman P., et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology: 2009; 72 12 1087 1094
29. Zoccolella S., Beghi E., Palagano G., et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci: 2008; 268 1-2 28 32
30. Küffner R., Zach N., Norel R., et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol: 2015; 33 1 51 57
31. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol: 2013; 9 11 617 628
32. Worms P. M. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci: 2001; 191 1-2 3 9
33. Huisman M. H., de Jong S. W., van Doormaal P. T., et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry: 2011; 82 10 1165 1170
34. Weisskopf M. G., O'Reilly E. J., McCullough M. L., et al. Prospective study of military service and mortality from ALS. Neurology: 2005; 64 1 32 37
35. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology: 2009; 73 20 1693 1698
36. Abel E. L. Football increases the risk for Lou Gehrig's disease, amyotrophic lateral sclerosis. Percept Mot Skills: 2007; 104 (3 Pt 2): 1251 1254
37. Chiò A., Benzi G., Dossena M., Mutani R., Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain: 2005; 128 Pt 3 472 476
38. Al-Chalabi A., Leigh P. N. Trouble on the pitch: are professional football players at increased risk of developing amyotrophic lateral sclerosis? Brain: 2005; 128 Pt 3 451 453
39. Hamidou B., Couratier P., Besançon C., Nicol M., Preux P. M., Marin B. Epidemiological evidence that physical activity is not a risk factor for ALS. Eur J Epidemiol: 2014; 29 7 459 475
40. Pupillo E., Messina P., Giussani G., et al. EURALS Consortium. Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol: 2014; 75 5 708 716
41. Turner M. R., Abisgold J., Yeates D. G., Talbot K., Goldacre M. J. Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. J Neurol Sci: 2010; 288 1-2 45 48
42. McKee A. C., Gavett B. E., Stern R. A., et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol: 2010; 69 9 918 929
43. O'Reilly E. J., Wang H., Weisskopf M. G., et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener: 2013; 14 3 205 211
44. Leblond C. S., Kaneb H. M., Dion P. A., Rouleau G. A. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol: 2014; 262 (Pt B): 91 101
45. Sreedharan J., Brown R. H. Jr. Amyotrophic lateral sclerosis: problems and prospects. Ann Neurol: 2013; 74 3 309 316
46. Peters O. M., Ghasemi M., Brown R. H. Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest: 2015; 125 6 2548
47. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron: 2011; 72 2 245 256
48. Gijselinck I., Van Langenhove T., van der Zee J., et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol: 2012; 11 1 54 65
49. Renton A. E., Majounie E., Waite A., et al. ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron: 2011; 72 2 257 268
50. Rosen D. R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature: 1993; 362 6415 59 62
51. Andersen P. M., Nilsson P., Ala-Hurula V., et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet: 1995; 10 1 61 66
52. Sreedharan J., Blair I. P., Tripathi V. B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science: 2008; 319 5870 1668 1672
53. Kwiatkowski T. J. Jr, Bosco D. A., Leclerc A. L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science: 2009; 323 5918 1205 1208
54. Smith B. N., Vance C., Scotter E. L., et al. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging: 2015; 36 3 1602.e17 1602.e27
55. Pensato V., Tiloca C., Corrado L., et al. SLAGEN Consortium. TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. J Neurol: 2015; 262 5 1376 1378
56. Johnson J. O., Mandrioli J., Benatar M., et al. ITALSGEN Consortium. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron: 2010; 68 5 857 864
57. González-Pérez P., Cirulli E. T., Drory V. E., et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology: 2012; 79 22 2201 2208
58. Kim H. J., Kim N. C., Wang Y. D., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature: 2013; 495 7442 467 473
59. Mitchell J., Paul P., Chen H. J., et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A: 2010; 107 16 7556 7561
60. Greenway M. J., Andersen P. M., Russ C., et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet: 2006; 38 4 411 413
61. Van Hoecke A., Schoonaert L., Lemmens R., et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med: 2012; 18 9 1418 1422
62. Cirulli E. T., Lasseigne B. N., Petrovski S., et al. FALS Sequencing Consortium. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science: 2015; 347 6229 1436 1441
63. Freischmidt A., Wieland T., Richter B., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci: 2015; 18 5 631 636
64. Traynor B. J., Alexander M., Corr B., Frost E., Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry: 2003; 74 9 1258 1261
65. Van den Berg J. P., Kalmijn S., Lindeman E., et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology: 2005; 65 8 1264 1267
66. Miller R. G., Jackson C. E., Kasarskis E. J., et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology: 2009; 73 15 1227 1233
67. Miller R. G., Jackson C. E., Kasarskis E. J., et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology: 2009; 73 15 1218 1226
68. Andersen P. M., Borasio G. D., Dengler R., et al. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol: 2005; 12 12 921 938
69. Bensimon G., Lacomblez L., Meininger V.; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med: 1994; 330 9 585 591
70. Lacomblez L., Bensimon G., Leigh P. N., et al. ALS/Riluzole Study Group-II. A confirmatory dose-ranging study of riluzole in ALS. Neurology: 1996; 47 6 04 S242 S250
71. Tavakoli M. Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage. Eur J Health Econ: 2002; 3 3 156 165
72. Groeneveld G. J., van Kan H. J., Lie-A-Huen L., Guchelaar H. J., van den Berg L. H. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin Pharmacol Ther: 2008; 83 5 718 722
73. Bensimon G., Lacomblez L., Delumeau J. C., Bejuit R., Truffinet P., Meininger V.; Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol: 2002; 249 5 609 615
74. Rudnicki S. A. Factors influencing a patient's decision regarding riluzole: an early experience. J Neurol Sci: 1997; 152 01 S80 S81
75. Miller R. G., Mitchell J. D., Moore D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev: 2012; 3 CD001447
76. Brooks B. R., Thisted R. A., Appel S. H., et al. AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology: 2004; 63 8 1364 1370
77. Pioro E. P., Brooks B. R., Cummings J., et al. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol: 2010; 68 5 693 702
78. Ho D. T., Ruthazer R., Russell J. A. Shoulder pain in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis: 2011; 13 1 53 55
79. Desport J. C., Preux P. M., Truong C. T., Courat L., Vallat J. M., Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord: 2000; 1 2 91 96
80. Reich-Slotky R., Andrews J., Cheng B., et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener: 2013; 14 3 212 216
81. Shimizu T., Nagaoka U., Nakayama Y., et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler: 2012; 13 4 363 366
82. Marin B., Desport J. C., Kajeu P., et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry: 2011; 82 6 628 634
83. Aydogdu I., Tanriverdi Z., Ertekin C. Dysfunction of bulbar central pattern generator in ALS patients with dysphagia during sequential deglutition. Clin Neurophysiol: 2011; 122 6 1219 1228
84. Kasarskis E. J., Scarlata D., Hill R., Fuller C., Stambler N., Cedarbaum J. M. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci: 1999; 169 1-2 118 125
85. Desport J. C., Mabrouk T., Bouillet P., Perna A., Preux P. M., Couratier P. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord: 2005; 6 2 88 93
86. Mitsumoto H., Davidson M., Moore D., et al. ALS CARE Study Group. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord: 2003; 4 3 177 185
87. Shaw A. S., Ampong M. A., Rio A., et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler: 2006; 7 1 16 21
88. Spataro R., Ficano L., Piccoli F., La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci: 2011; 304 1-2 44 48
89. Atassi N., Cudkowicz M. E., Schoenfeld D. A. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler: 2011; 12 4 272 277
90. Martin L., Blomberg J., Lagergren P. Patients' perspectives of living with a percutaneous endoscopic gastrostomy (PEG). BMC Gastroenterol: 2012; 12 126
91. Rio A., Ellis C., Shaw C., et al. Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. J Hum Nutr Diet: 2010; 23 4 408 415
92. Thurman D. J., Stevens J. A., Rao J. K.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology: 2008; 70 6 473 479
93. Gil J., Funalot B., Verschueren A., et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol: 2008; 15 11 1245 1251
94. Green J. R., Yunusova Y., Kuruvilla M. S., et al. Bulbar and speech motor assessment in ALS: challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener: 2013; 14 7-8 494 500
95. Bourke S. C., Tomlinson M., Williams T. L., Bullock R. E., Shaw P. J., Gibson G. J. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol: 2006; 5 2 140 147
96. Pinto A. C., Evangelista T., Carvalho M., Alves M. A., Sales Luís M. L. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci: 1995; 129 (Suppl): 19 26
97. Miller T. M., Smith R. A., Kordasiewicz H., Kaspar B. K. Gene-targeted therapies for the central nervous system. Arch Neurol: 2008; 65 4 447 451